Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Gordon Lang

General Practice Wakeeney, KS Medical Doctor

NPI 1790890200 CMS profile 217861

333 N 14Th St, Wakeeney, KS 67672

Open in the dashboard

General payments

$1,501

107 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Gordon Lang of Wakeeney, KS is reported in the CMS Open Payments database as having received $1,501 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $77 6
2020 General $442 33
2019 General $981 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gordon Lang
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Gordon Lang were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Gordon Lang General Practice median Middle half National median
2019 $981 $107 $37–$285 $163
2020 $442 $75 $25–$213 $114
2021 $77 $93 $30–$272 $132
2022 $0 $103 $36–$279 $149
2023 $0 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $0 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Sunovion Pharmaceuticals Inc. $481 37 payments
  2. Amgen Inc. $227 12 payments
  3. Pfizer Inc. $172 15 payments
  4. Novo Nordisk Inc $118 8 payments
  5. Mylan Specialty L.P. $72 5 payments
  6. AstraZeneca Pharmaceuticals LP $62 5 payments
  7. Ironwood Pharmaceuticals, Inc $48 3 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $45 3 payments
  9. Radius Health, Inc. $43 2 payments
  10. Janssen Pharmaceuticals, Inc $41 3 payments
  11. Other $191 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $1,501 107 payments
Products named General payments · program years 2019–2021
  1. LONHALA MAGNAIR $368 26 payments
  2. Prolia $214 11 payments
  3. EVENITY $175 9 payments
  4. APTIOM $113 11 payments
  5. BROVANA $99 7 payments
  6. UTIBRON NEOHALER $99 7 payments
  7. SEEBRI NEOHALER $99 7 payments
  8. ELIQUIS $98 8 payments
  9. Ozempic $94 7 payments
  10. CHANTIX $76 7 payments
  11. Other $1,028 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record